Inhibitor Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020
March 26, 2021 at 09:02 am EDT
Share
Inhibitor Therapeutics, Inc. announced earnings results for the full year ended December 31, 2020. For the full year, the company announced operating loss was USD 1.058 million compared to USD 2.747 million a year ago. Net loss was USD 1.057 million compared to USD 2.733 million a year ago. Basic eps - continuing operations was USD 0 compared to basic loss per share from continuing operations of USD 0.01 a year ago.
Inhibitor Therapeutics, Inc. is a pharmaceutical development company. The Company is focused on developing and commercializing therapeutics based on already approved active pharmaceuticals that have patent-protected methods of use and/or methods of delivery for patients with certain cancers and certain non-cancerous proliferation disorders. Its primary focus is on the development of therapies initially for basal cell carcinoma (BCC), prostate and lung cancers in the United States utilizing itraconazole, a drug approved by the United States Food and Drug Administration (FDA) to treat fungal infections. The Company has developed intellectual property and know-how related to the treatment of cancer patients using itraconazole. The Company's intellectual property in the form of issued United States patents includes treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors, and treatment of lung cancer using hedgehog pathway inhibitors.
INHIBITOR THERAPEUTICS, INC. 
